US Stocks Estimated Below Intrinsic Value In October 2024
In This Article:
As of October 2024, the U.S. stock market is experiencing a notable upswing, with major indices like the S&P 500 and Dow Jones Industrial Average reaching record highs amid their longest winning streaks of the year. This positive momentum highlights the potential for investors to explore stocks that may still be trading below their intrinsic value despite broader market gains. Identifying such undervalued stocks requires careful analysis of financial health and growth prospects in relation to current economic conditions, which can provide opportunities for strategic investment decisions.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Silicon Motion Technology (NasdaqGS:SIMO) | $55.94 | $107.01 | 47.7% |
| MidWestOne Financial Group (NasdaqGS:MOFG) | $29.69 | $57.34 | 48.2% |
| Associated Banc-Corp (NYSE:ASB) | $22.85 | $43.82 | 47.9% |
| Atlanticus Holdings (NasdaqGS:ATLC) | $37.39 | $72.49 | 48.4% |
| Avidbank Holdings (OTCPK:AVBH) | $19.60 | $37.73 | 48.1% |
| EVERTEC (NYSE:EVTC) | $33.28 | $66.37 | 49.9% |
| Vitesse Energy (NYSE:VTS) | $25.00 | $49.16 | 49.1% |
| AeroVironment (NasdaqGS:AVAV) | $216.97 | $416.68 | 47.9% |
| Vasta Platform (NasdaqGS:VSTA) | $2.5568 | $4.87 | 47.5% |
| Viking Holdings (NYSE:VIK) | $38.97 | $74.65 | 47.8% |
Let's uncover some gems from our specialized screener.
Repligen
Overview: Repligen Corporation develops and commercializes bioprocessing technologies and systems for biological drug manufacturing globally, with a market cap of approximately $8.23 billion.
Operations: The company's revenue is primarily derived from its Medical Products segment, which generated $602.35 million.
Estimated Discount To Fair Value: 22%
Repligen is trading at US$146.95, below its estimated fair value of US$188.49, indicating potential undervaluation based on cash flows. Despite a challenging year with reduced net income and earnings per share, the company reaffirmed its 2024 revenue guidance between $627 million and $642 million. Analysts expect the stock price to rise by 30.5%, supported by forecasted annual profit growth above market averages over the next three years.
-
According our earnings growth report, there's an indication that Repligen might be ready to expand.
-
Take a closer look at Repligen's balance sheet health here in our report.
Crown Holdings
Overview: Crown Holdings, Inc., along with its subsidiaries, operates in the packaging industry both in the United States and internationally, with a market cap of $11.55 billion.
Operations: The company's revenue segments include Americas Beverage at $5.21 billion, European Beverage at $2.01 billion, Transit Packaging at $2.19 billion, and Asia Pacific at $1.17 billion.